Literature DB >> 22805083

[Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: a randomized controlled trial].

Lu Yu1, Shui-miao Lin, Ru-qian Zhou, Wei-jun Tang, Pin-xian Huang, Ying Dong, Jian Wang, Zhi-hua Yu, Jiu-lin Chen, Li Wei, San-li Xing, Hui-juan Cao, Hong-bin Zhao.   

Abstract

BACKGROUND: Alzheimer disease (AD) is a chronic neurodegenerative disease that is characterized by its gradual progression. At present, the cause and mechanism of AD are yet unclear, and there is no effective therapy for treating it. With development of global aging, the prevalence rate of AD is increasing. The life quality of elderly people is affected severely by AD that is ultimately life-threatening. Recently, study on treating AD with traditional Chinese medicine (TCM) has deepened.
OBJECTIVE: To explore the therapeutic effects of a syndrome differentiation-based TCM regime in treating patients with mild to moderate AD for improving cognition, and to evaluate the changes in brain function of AD patients observed by resting-state functional magnetic resonance imaging (fMRI) technique. DESIGN, SETTING, PARTICIPANTS AND
INTERVENTIONS: Adopting the internationally recognized criteria developed by National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association, the clinical trial was conducted on 131 patients with mild to moderate AD from 5 communities and 7 social welfare institutions. Participants were accepted after informed consent was received, and laboratory tests and a head imaging study were conducted. The patients were randomly divided into Chinese medicine group (CMG) (66 cases) or Western medicine group (WMG) (65 cases). Patients in the CMG were treated monthly with Chinese medicine according to syndrome differentiation. Patients in the WMG were treated with donepezil at a dose of 5 mg once daily. The therapeutic course lasted 48 weeks. MAIN OUTCOME MEASURES: The scores of Mini-Mental State Examination (MMSE), Fuld Object-Memory Evaluation (FOM), Block Design (BD) and Digit Span (DS) were used to evaluate the cognitive function; resting-state fMRI was used for observing brain function. The questionnaires and fMRI were performed before and after treatments.
RESULTS: The cognitive functions of the patients in the CMG and WMG were improved after treatment. MMSE score was improved significantly in both groups (P<0.05 or P<0.001). After 48 weeks of treatment, 70.91% patients in the CMG had an improved MMSE score and 20% got worse, however, 55.77% patients in the WMG were improved in MMSE score and 34.62% got worse. Scores of FOM denominator and BD increased significantly in both groups; scores of FOM numerator and DS were also increased in the CMG (P<0.05 or P<0.01). The results of fMRI suggested that both Chinese medicine and donepezil treatment improved the connectivity between posterior cingulated gyrus and specific areas in the brain. The influence range of Chinese medicine primarily impacted on the left parietal lobe, being less than the influence range of donepezil, which primarily affected both sides of frontal lobes.
CONCLUSION: TCM treatment based on syndrome differentiation is effective in improving cognitive function of patients with mild to moderate AD and increasing the brain function by increasing connectivity between posterior cingulated gyrus and specific areas in the brain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22805083     DOI: 10.3736/jcim20120707

Source DB:  PubMed          Journal:  Zhong Xi Yi Jie He Xue Bao        ISSN: 1672-1977


  8 in total

1.  Di-Huang-Yi-Zhi herbal formula attenuates amyloid-β-induced neurotoxicity in PC12 cells.

Authors:  Hong-Mei An; Chen Lin; Chao Gu; Jin-Jun Chen; Wen-Xian Sun; Miao Jin; Tian-Li Zhang; Ming-Feng Qiu; Bing Hu
Journal:  Exp Ther Med       Date:  2017-04-20       Impact factor: 2.447

2.  Chinese Medicine for Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Hang-Kun Ma; Yue Liu; Bo Li; Ying Zhang; Lin-Juan Sun; Feng-Qin Xu
Journal:  Chin J Integr Med       Date:  2018-09-22       Impact factor: 1.978

3.  History and experience: a survey of traditional chinese medicine treatment for Alzheimer's disease.

Authors:  Ping Liu; Mingwang Kong; Shihe Yuan; Junfeng Liu; Ping Wang
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-29       Impact factor: 2.629

Review 4.  Traditional East Asian Herbal Medicine Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis.

Authors:  JiEun Lee; Seungwon Kwon; Chul Jin; Seung-Yeon Cho; Seong-Uk Park; Woo-Sang Jung; Sang-Kwan Moon; Jung-Mi Park; Chang-Nam Ko; Ki-Ho Cho
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-31

5.  Herbal Medicine for Patients with Cognitive Impairment: An Observational Study.

Authors:  Yujin Choi; Ae-Ran Kim; Ji-Yoon Lee; Hae Sook Kim; Changsop Yang; Jae Kwang Kim; Younghoon Go; In Chul Jung
Journal:  Neuropsychiatr Dis Treat       Date:  2021-10-21       Impact factor: 2.570

6.  Effect of acupuncture with donepezil based on syndrome differentiation on cognitive function in patients with mild-to-moderate Alzheimer's disease: a study protocol for a multicenter randomized controlled trial.

Authors:  Qin-Hui Fu; Jian Pei; Hou-Guang Zhou; Tao Wang; Yi-Jun Zhan; Lin Tao; Jia Xu; Qian Zhou; Liao-Yao Wang
Journal:  Trials       Date:  2022-08-19       Impact factor: 2.728

7.  A Two-Year Treatment of Amnestic Mild Cognitive Impairment using a Compound Chinese Medicine: A Placebo Controlled Randomized Trial.

Authors:  Junying Zhang; Zhen Liu; Huamin Zhang; Caishui Yang; He Li; Xin Li; Kewei Chen; Zhanjun Zhang
Journal:  Sci Rep       Date:  2016-07-04       Impact factor: 4.379

8.  Effect of the herbal formulation Shen-Zhi-Ling on an APP/PS1 mouse model of Alzheimer's disease by modulating the biliverdin reductase/heme oxygenase 1 system.

Authors:  Sanli Xing; Dingzhu Shen; Chuan Chen; Beiling Wu; Huiying Chi
Journal:  Exp Ther Med       Date:  2017-07-09       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.